Lantheus Hldg
Price
Price
Frequently asked questions
What is Lantheus Hldg's market capitalization?
What is Lantheus Hldg's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Lantheus Hldg?
What are the analyst ratings and target price for Lantheus Hldg's stock?
What is Lantheus Hldg's revenue over the trailing twelve months?
What is the EBITDA for Lantheus Hldg?
What is the free cash flow of Lantheus Hldg?
What is the 5-year beta of Lantheus Hldg's stock?
How many employees does Lantheus Hldg have, and what sector and industry does it belong to?
What is the free float of Lantheus Hldg's shares?
Financials
Market Cap
$6.07B5Y beta
0.47EPS (TTM)
$6.017Free Float
67.81MP/E ratio (TTM)
14.51Revenue (TTM)
$1.50BEBITDA (TTM)
$536.69MFree Cashflow (TTM)
$378.64MPricing
Analyst Ratings
The price target is $104.90 and the stock is covered by 10 analysts.
Buy
9
Hold
1
Sell
0
Information
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.
834
Medical Equipment & Supplies
Health Care
Identifier
ISIN
Primary Ticker